In part 2 of this Exclusive Interview, DIC Publisher Steve Freed asks about the success of anti-VEGF agents with lower A1Cs.

In this week's Homerun Slides, prioritizing patient characteristics to determine best type 2 treatment agent.

Transport of proinsulin from the ER to Golgi apparatus: After proinsulin is translocated into the lumen of the ER, it is then delivered in transport “COP-coated vesicles” to the cis-Golgi apparatus. Up until relatively recently, it was thought that newly synthesized proinsulin was passed from the cis-Golgi network “stack” via the medial- to the trans-stack of the Golgi apparatus stacks in “COP”-coated vesicles,

Part 2 of our ADA Rundown checks out the latest information on competing long-acting insulins, and the ongoing research into potential class effect benefits for cardiovascular outcomes: as data shows CV benefits for DPP-4 and SGLT-2 treatments, are GLP-1 treatments under pressure?

In part 1 of our ADA Rundown, we look at cardiovascular benefits for multiple drugs, new combination treatments, and the possibility that Invokana's weight loss benefits may also apply to people who don't have diabetes.

Most times when you get a Key Opinion Leader and well-known researcher like Dr. George Bakris to talk about trends in drugs, they want all the spotlight. In addition, they often won’t want anything to do with the business side of diabetes. However, due to the close relationship that our …

With so much breaking news surrounding SGLT-2 Inhibitors at ADA, what conclusions can we draw? Viewpoints from our guest editorialist David Kliff, and DIC advisory board member Dr. George Bakris.

Would you be interested in seeing the news briefings from the ADA meeting? Topics include beta-cell replacement, closed loop systems, CVD and diabetes, etc., and feature all the top doctors on each. They last about 45 minutes. Follow the link to cast your vote!

Steve, Joy and I had full days at the ADA Scientific meeting last week. Steve and Joy were busy interviewing key opinion leaders and researchers, and I was combing the posters and abstracts looking for the latest data that affects your practice — and possibly your choice of medications. There were plenty …

At the 2016 conference in New Orleans, the latest research on SGLT-2 Inhibitors was on display.